Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
Head of Roche Diagnostics’ North America Region Matt Sause will become CEO of the diagnostics division at Roche (SIX:ROG; OTCQX:RHHBY), effective Jan. 1. Sause succeeds Thomas Schinecker, who will become the company’s CEO on March 15. Sause joined Roche in 2002 as molecular diagnostics account manager and became VP of lifecycle leader in 2018, before assuming his current role as president and CEO for Roche Diagnostics North America.
Gout and chronic kidney disease company Urica Therapeutics Inc. named Jay Kranzler as chairman and CEO. Kranzler was VP and global head of external R&D innovation and worldwide R&D strategic investments at Pfizer Inc. (NYSE:PFE), before which he was chair and CEO at Cypress Bioscience Inc. The company also appointed Vibeke Strand, adjunct clinical professor in the division of immunology/rheumatology at Stanford University, to its board. Urica Therapeutics Inc. is a subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO)...